REGULATORY ACTIVITY

OverviewUnited StatesCanada • BrazilEuropean Medicines Agency (EMA)France • GermanySwedenUnited KingdomAustralia & New Zealand • Japan • KoreaPosts

UK: Medicines and Healthcare products Regulatory Agency (MHRA)

Visit agency website

Mail+ announces that the UK’s Medicines and Healthcare Products Agency (MHRA) will launch a safety review of finasteride (no official link available as of March 4, 2023) – March 4, 2023.

Freedom of Information requests

Published 7 Mar 2023

Published 1 Jun 2022

Published 29 Dec 2021

Finasteride: rare reports of depression and suicidal thoughts – 24 May 2017

• since finasteride has been marketed there have been a number of spontaneous adverse drug reaction reports suggesting a possible link to depression, and in rare cases, suicidal thoughts

• advise patients to stop finasteride 1 mg (Propecia) immediately if they develop depression and inform a healthcare professional

• be aware that the product information for finasteride 5 mg (Proscar) already lists depression as a possible adverse reaction

Finasteride: potential risk of male breast cancer – 11 Dec 2014

Medicines and Healthcare Products Regulatory Agency, United Kingdom. Finasteride and the risk of male breast cancer. December 2009. Accessed July 16, 2022.

Public Assessment Report – Finasteride 1 mg – 15 Jul 2009. Section 4.8 notes: “Persistence of erectile dysfunction after discontinuation of treatment with PROPECIA has been reported in post-marketing use.”